Safety of Bisphosphonates

Rheumatic Disease Clinics of North America

Volumn 38, Issue 4, 2012, Pages 681-705

  Orozco, Catalina ^a   Maalouf, Naim M ^b  

^a Rheumatology Associates   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Atrial fibrillation; Atypical femoral fracture; Bisphosphonate; Esophageal cancer; Esophagitis; Osteonecrosis of the jaw; Safety; Side effects

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHLORHEXIDINE GLUCONATE; CLODRONIC ACID; CREATININE; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PARACETAMOL; PLACEBO; RISEDRONIC ACID; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ACUTE PHASE RESPONSE; ARTHRALGIA; BLURRED VISION; BONE DENSITY; BONE PAIN; BONE RADIOGRAPHY; BONE TURNOVER; CANCER RISK; CATARACT; CHILL; CLINICAL TRIAL (TOPIC); CONJUNCTIVITIS; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EPISCLERITIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS DISEASE; EYE DISEASE; EYE INFLAMMATION; EYE PAIN; FATIGUE; FEMUR FRACTURE; FOCAL GLOMERULOSCLEROSIS; FRACTURE FIXATION; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GLOMERULOSCLEROSIS; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; HYPERBARIC OXYGEN; HYPOCALCEMIA; HYPOMAGNESEMIA; INFECTION; INTRAMEDULLARY NAILING; IRIDOCYCLITIS; JAW OSTEONECROSIS; KIDNEY FAILURE; KIDNEY INJURY; LONG TERM CARE; LOW DRUG DOSE; MORBIDITY; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NONHUMAN; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT GUIDANCE; PHOTOPHOBIA; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA EDEMA; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCLERA DISEASE; SCLERA PERFORATION; SCLERITIS; SIDE EFFECT; SPINE FRACTURE; TREATMENT DURATION; VITAMIN D DEFICIENCY;

ATRIAL FIBRILLATION; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS; HUMANS; OSTEOPOROSIS; RISK ASSESSMENT;

EID: 84868337594     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2012.09.001     Document Type: Review

References (149)

1. Background document for meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. Available at: Accessed September 17, 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM270958.pdf.
2. Rodan G.A., Fleisch H.A. Bisphosphonates: mechanisms of action. J Clin Invest 1996, 97:2692-2696.
3. Sato M., Grasser W., Endo N., et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991, 88:2095-2105.
4. Khan S.A., Kanis J.A., Vasikaran S., et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997, 12:1700-1707.
5. Russell R.G., Watts N.B., Ebetino F.H., et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
6. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
7. Reginster J., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83-91.
8. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
9. Chesnut I.C., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
10. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344-1352.
11. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344:333-340.
12. Harris S.T., Blumentals W.A., Miller P.D. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008, 24:237-245.
13. Silverman S.L., Watts N.B., Delmas P.D., et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007, 18:25-34.
14. Silverman S.L. Osteoporosis therapies: evidence from health-care databases and observational population studies. Calcif Tissue Int 2010, 87:375-384.
15. Miller P.D. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep 2005, 3:103-110.
16. Watts N.B., Lewiecki E.M., Bonnick S.L., et al. Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res 2009, 24:1643-1646.
17. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296:2927-2938.
18. Schwartz A.V., Bauer D.C., Cummings S.R., et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010, 25:976-982.
19. Black D.M., Reid I.R., Boonen S., et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012, 27:243-254.
20. Eastell R., Hannon R.A., Wenderoth D., et al. Effect of stopping risedronate after long-term treatment on bone turnover. J Clin Endocrinol Metab 2011, 96:3367-3373.
21. Liberman U.A., Weiss S.R., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995, 333:1437-1443.
22. Ravn P., Clemmesen B., Riis B.J., et al. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996, 19:527-533.
23. Reid I.R., Brown J.P., Burckhardt P., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346:653-661.
24. Odvina C.V., Zerwekh J.E., Rao D.S., et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
25. Donnelly E., Meredith D.S., Nguyen J.T., et al. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res 2012, 27:672-678.
26. Goh S.K., Yang K.Y., Koh J.S., et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007, 89:349-353.
27. Armamento-Villareal R., Napoli N., Diemer K., et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 2009, 85:37-44.
28. Park-Wyllie L.Y., Mamdani M.M., Juurlink D.N., et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011, 305:783-789.
29. Feldstein A.C., Black D., Perrin N., et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 2012, 27:977-986.
30. Shane E., Burr D., Ebeling P.R., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294.
31. Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res, in press. doi:. http://dx.doi.org/10.1002/jbmr.1719.
32. Wang Z., Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res 2011, 26:553-560.
33. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24:1095-1102.
34. Vestergaard P., Schwartz F., Rejnmark L., et al. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int 2011, 22:993-1001.
35. Nieves J.W., Bilezikian J.P., Lane J.M., et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2010, 21:399-408.
36. Meier R.P., Perneger T.V., Stern R., et al. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use atypical femoral fractures and bisphosphonate use. Arch Intern Med 2012, 172:930-936.
37. Schilcher J., Michaelsson K., Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011, 364:1728-1737.
38. Ing-Lorenzini K., Desmeules J., Plachta O., et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 2009, 32:775-785.
39. Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int 2011, 22:2951-2961.
40. Allen M.R., Gineyts E., Leeming D.J., et al. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int 2008, 19:329-337.
41. Donnelly E., Meredith D.S., Nguyen J.T., et al. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res 2012, 27:672-678.
42. Somford M.P., Draijer F.W., Thomassen B.J., et al. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 2009, 24:1736-1740.
43. Fournier P., Boissier S., Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002, 62:6538-6544.
44. Lo J.C., Huang S.Y., Lee G.A., et al. Clinical correlates of atypical femoral fracture. Bone 2012, 51:181-184.
45. Kwek E.B., Goh S.K., Koh J.S., et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury 2008, 39:224-231.
46. Fournier M.R., Targownik L.E., Leslie W.D. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures. Maturitas 2009, 64:9-13.
47. Gomberg S.J., Wustrack R.L., Napoli N., et al. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab 2011, 96:1627-1632.
48. Donnelly E., Saleh A., Unnanuntana A., et al. Atypical femoral fractures: epidemiology, etiology, and patient management. Curr Opin Support Palliat Care 2012, 6:348-354.
49. Carvalho N.N., Voss L.A., Almeida M.O., et al. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab 2011, 96:2675-2680.
50. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479-1491.
51. Solomon DH, Mercer E, Woo SB, et al. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporos Int, in press.
52. Tennis P., Rothman K.J., Bohn R.L., et al. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf 2012, 21:810-817.
53. Durie B.G., Katz M., Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005, 353:99-102. [discussion: 99].
54. Fellows J.L., Rindal D.B., Barasch A., et al. ONJ in two dental practice-based research network regions. J Dent Res 2011, 90:433-438.
55. Woo S.B., Hellstein J.W., Kalmar J.R. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006, 144:753-761.
56. Barasch A., Cunha-Cruz J., Curro F.A., et al. Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res 2011, 90:439-444.
57. Kyrgidis A., Verrou E. Fatigue in bone: a novel phenomenon attributable to bisphosphonate use. Bone 2010, 46:556. [author reply: 7-8].
58. Dodson T.B., Raje N.S., Caruso P.A., et al. Case records of the Massachusetts General Hospital. Case 9-2008. A 65-year-old woman with a nonhealing ulcer of the jaw. N Engl J Med 2008, 358:1283-1291.
59. Krishnan A., Arslanoglu A., Yildirm N., et al. Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance imaging findings. J Comput Assist Tomogr 2009, 33:298-304.
60. Reid I.R., Bolland M.J., Grey A.B. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone 2007, 41:318-320.
61. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006, 137:1144-1150.
62. Bisphosphonate-associated osteonecrosis of the jaw 2006, American College of Rheumatology, Atlanta (GA). American College of Rheumatology (Ed.).
63. Rizzoli R., Burlet N., Cahall D., et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008, 42:841-847.
64. Iwamoto J., Yago K., Sato Y., et al. Teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw in an elderly Japanese woman with severe osteoporosis. Clin Drug Investig 2012, 32:547-553.
65. Lau A.N., Adachi J.D. Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J Rheumatol 2009, 36:1835-1837.
66. Cheung A., Seeman E. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med 2010, 363:2473-2474.
67. Freiberger J.J., Padilla-Burgos R., McGraw T., et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. J Oral Maxillofac Surg 2012, 70:1573-1583.
68. Voss PJ, Joshi Oshero J, Kovalova-Muller A, et al. Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients. J Craniomaxillofac Surg, in press.
69. Vescovi P., Merigo E., Meleti M., et al. Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. J Oral Pathol Med 2012, 41:214-221.
70. de Groen P.C., Lubbe D.F., Hirsch L.J., et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996, 335:1016-1021.
71. Cryer B., Bauer D.C. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?. Mayo Clin Proc 2002, 77:1031-1043.
72. Bauer D.C., Black D., Ensrud K., et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000, 160:517-525.
73. Strampel W., Emkey R., Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 2007, 30:755-763.
74. Wysowski D.K. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360:89-90.
75. Green J., Czanner G., Reeves G., et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010, 341:c4444.
76. Cardwell C.R., Abnet C.C., Cantwell M.M., et al. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010, 304:657-663.
77. Abrahamsen B., Eiken P., Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360:1789. [author reply: 91-2].
78. Vestergaard P. Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis. Calcif Tissue Int 2011, 89:434-441.
79. Abrahamsen B., Pazianas M., Eiken P., et al. Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res 2012, 27:679-686.
80. Solomon D.H., Patrick A., Brookhart M.A. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360:1789-1790. [author reply: 91-2].
81. Chen Y.M., Chen D.Y., Chen L.K., et al. Alendronate and risk of esophageal cancer: a nationwide population-based study in Taiwan. J Am Geriatr Soc 2011, 59:2379-2381.
82. Ho Y.F., Lin J.T., Wu C.Y. Oral bisphosphonates and risk of esophageal cancer: a dose-intensity analysis in a nationwide population. Cancer Epidemiol Biomarkers Prev 2012, 21:993-995.
83. U.S. Food and Drug Administration. FDA Drug Safety Communication: Ongoing safety review of oral osteoporosis drugs (bisphosphonates) and potential increased risk of esophageal cancer. Available at: Accessed September 17, 2012. http://www.fda.gov/drugs/drugsafety/ucm263320.htm.
84. Cummings S.R., Schwartz A.V., Black D.M. Alendronate and atrial fibrillation. N Engl J Med 2007, 356:1895-1896.
85. Barrett-Connor E., Swern A.S., Hustad C.M., et al. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporos Int 2012, 23:233-245.
86. Karam R., Camm J., McClung M. Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 2007, 357:712-713. [author reply: 4-5].
87. Lewiecki E.M., Cooper C., Thompson E., et al. Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Pract 2010, 64:821-826.
88. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
89. Bundred N.J., Campbell I.D., Davidson N., et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 2008, 112:1001-1010.
90. Hershman D.L., McMahon D.J., Crew K.D., et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008, 26:4739-4745.
91. Smith M.R., Eastham J., Gleason D.M., et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008-2012.
92. U.S. Food and Drug Administration. Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates. Available at: Accessed September 17, 2012. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm.
93. Abrahamsen B., Eiken P., Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 2009, 265:581-592.
94. Vestergaard P., Schwartz K., Pinholt E.M., et al. Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study. Calcif Tissue Int 2010, 86:335-342.
95. Bunch T.J., Anderson J.L., May H.T., et al. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 2009, 103:824-828.
96. Huang W.F., Tsai Y.W., Wen Y.W., et al. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene. Menopause 2010, 17:57-63.
97. Rhee C.W., Lee J., Oh S., et al. Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis. Osteoporos Int 2012, 23:247-254.
98. Heckbert S.R., Li G., Cummings S.R., et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008, 168:826-831.
99. Sorensen H.T., Christensen S., Mehnert F., et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008, 336:813-816.
100. Grosso A., Douglas I., Hingorani A., et al. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS One 2009, 4:e4720.
101. Loke Y.K., Jeevanantham V., Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 2009, 32:219-228.
102. Bhuriya R., Singh M., Molnar J., et al. Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 2010, 142:213-217.
103. Mak A., Cheung M.W., Ho R.C., et al. Bisphosphonates and atrial fibrillation: bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord 2009, 10:113.
104. Kim S.Y., Kim M.J., Cadarette S.M., et al. Bisphosphonates and risk of atrial fibrillation: a meta-analysis. Arthritis Res Ther 2010, 12:R30.
105. Howard P.A., Barnes B.J., Vacek J.L., et al. Impact of bisphosphonates on the risk of atrial fibrillation. Am J Cardiovasc Drugs 2010, 10:359-367.
106. Delmas P.D., Adami S., Strugala C., et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006, 54:1838-1846.
107. Reid I.R., Gamble G.D., Mesenbrink P., et al. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 2010, 95:4380-4387.
108. Bertoldo F., Pancheri S., Zenari S., et al. Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res 2010, 25:447-454.
109. Srivastava T., Dai H., Haney C.J., et al. Serum 25-hydroxyvitamin D level and acute-phase reaction following initial intravenous bisphosphonate. J Bone Miner Res 2011, 26:437-438.
110. Olson K., Van Poznak C. Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract 2007, 13:223-229.
111. Thompson K., Roelofs A.J., Jauhiainen M., et al. Activation of gammadelta T cells by bisphosphonates. Adv Exp Med Biol 2010, 658:11-20.
112. Dicuonzo G., Vincenzi B., Santini D., et al. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res 2003, 23:649-654.
113. Thompson K., Rogers M.J. Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro. J Bone Miner Res 2004, 19:278-288.
114. Hewitt R.E., Lissina A., Green A.E., et al. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 2005, 139:101-111.
115. Silverman S.L., Kriegman A., Goncalves J., et al. Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid. Osteoporos Int 2011, 22:2337-2345.
116. Thompson K., Keech F., McLernon D.J., et al. Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women. Bone 2011, 49:140-145.
117. Srivastava T., Haney C.J., Alon U.S. Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion. J Bone Miner Res 2009, 24:334-337.
118. Makras P., Anastasilakis A.D., Polyzos S.A., et al. No effect of rosuvastatin in the zoledronate-induced acute-phase response. Calcif Tissue Int 2011, 88:402-408.
119. Tanvetyanon T., Stiff P.J. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006, 17:897-907.
120. Macarol V., Fraunfelder F.T. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 1994, 118:220-224.
121. McKague M., Jorgenson D., Buxton K.A. Ocular side effects of bisphosphonates: a case report and literature review. Can Fam Physician 2010, 56:1015-1017.
122. Etminan M., Forooghian F., Maberley D. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. CMAJ 2012, 184:E431-E434.
123. Mbekeani J.N., Slamovits T.L., Schwartz B.H., et al. Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 1999, 117:837-838.
124. French D.D., Margo C.E. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina 2008, 28:889-893.
125. Wysowski D.K., Chang J.T. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 2005, 165:346-347.
126. U.S. Food and Drug Administration. Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa) Information. Available at: Accessed September 17, 2012. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm101551.htm.
127. Caplan L., Pittman C.B., Zeringue A.L., et al. An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy. Mayo Clin Proc 2010, 85:341-348.
128. Body J.J., Pfister T., Bauss F. Preclinical perspectives on bisphosphonate renal safety. Oncologist 2005, 10(Suppl 1):3-7.
129. Rosen L.S., Gordon D., Kaminski M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98:1735-1744.
130. Berenson J.R., Boccia R., Lopez T., et al. Results of a multicenter open-label randomized trial evaluating infusion duration of zoledronic acid in multiple myeloma patients (the ZMAX trial). J Support Oncol 2011, 9:32-40.
131. Markowitz G.S., Appel G.B., Fine P.L., et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001, 12:1164-1172.
132. U.S. Food and Drug Administration. FDA drug safety communication: new contraindication and updated warning on kidney impairment for Reclast (zoledronic acid). Available at: Accessed September 17, 2012. http://www.fda.gov/Drugs/DrugSafety/ucm270199.htm.
133. Miller P.D. The kidney and bisphosphonates. Bone 2011, 49:77-81.
134. Hirschberg R. Renal complications from bisphosphonate treatment. Curr Opin Support Palliat Care 2012, 6:342-347.
135. Barri Y.M., Munshi N.C., Sukumalchantra S., et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004, 65:634-641.
136. Banerjee D., Asif A., Striker L., et al. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 2003, 41:E18.
137. Yilmaz M., Taninmis H., Kara E., et al. Nephrotic syndrome after oral bisphosphonate (alendronate) administration in a patient with osteoporosis. Osteoporos Int 2012, 23:2059-2062.
138. Bodmer M., Amico P., Mihatsch M.J., et al. Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient. Nephrol Dial Transplant 2007, 22:2366-2370.
139. Maalouf N.M., Heller H.J., Odvina C.V., et al. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract 2006, 12:48-53.
140. Chesnut C.H., McClung M.R., Ensrud K.E., et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995, 99:144-152.
141. Harris S.T., Gertz B.J., Genant H.K., et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1993, 76:1399-1406.
142. Mortensen L., Charles P., Bekker P.J., et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998, 83:396-402.
143. Corporation N.P. Highlights of prescribing information 2011, Novartis, East Hanover (NJ), Available at:. http://www.pharma.us.novartis.com/product/pi/pdf/reclast.pdf.
144. Chennuru S., Koduri J., Baumann M.A. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid. Intern Med J 2008, 38:635-637.
145. Tsourdi E., Rachner T.D., Gruber M., et al. Seizures associated with zoledronic acid for osteoporosis. J Clin Endocrinol Metab 2011, 96:1955-1959.
146. Papapoulos S.E., Harinck H.I., Bijvoet O.L., et al. Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD. Bone Miner 1986, 1:69-78.
147. Quandt S.A., Thompson D.E., Schneider D.L., et al. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc 2005, 80:343-349.
148. Watts N.B., Diab D.L. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010, 95:1555-1565.
149. Watts N.B., Bilezikian J.P., Camacho P.M., et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 2010, 16(Suppl 3):1-37.